2022 Deal-Making Snapshot: One Big Deal Didn’t Change The Downward Trends

Amgen/Horizon Buyout Lessened Decline

Even with Amgen’s $27.8bn acquisition of Horizon in mid-December, biopharma M&A volume, total value and average deal value all dropped substantially from 2021.

business documents accounting with calculator and magnifying glass. concept for financial
2022 saw a significant decline in biopharma M&A activity

Despite continuing normalization two years into the COVID-19 pandemic, 2022 was shaping up to be a year of significant downturn in biopharmaceutical merger-and-acquisition activity. The year closed out with a deal big enough – Amgen, Inc. acquiring Horizon Therapeutics plc for $27.8bn – to shift the full-year statistics. Even with that transaction, however, M&A deal volume, total reported value and total average value dropped substantially from 2021.

The difference really was just a matter of degree, though. Factoring in the Amgen buyout, M&A total value declined 40% from 2021, while average deal value (meaning the reported amount paid, without factoring in any downstream payments such as milestone fees or contingent value rights) fell by 32%. (Also see "Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover" - Scrip, 12 December, 2022

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business